In the second model, anti-CD47 showed additive effect when combined with T-DM1 and enhanced the anti-tumor activity when combined anti-CD47 + T-DM1 compared to T-DM1 alone or paclitaxel (Supplementary Fig. 6B). This evidence concerns the gene CD47 and neoplasm.